Optimization and standardization in stem cell manufacturing for the fight against COVID-19

Presented by Donna Chang, Hope Biosciences The pandemic has forced the drug development industry to move at an unprecedented pace. Cellular therapies are finally being looked at as a possibility for immunomodulation and tissue regeneration. However, the existing challenges and limitations in delivering these therapies, are coming to light. Since its inception, Hope Biosciences has been working on solutions to deliver high quality, standardized, fresh mesenchymal stem cells - on-demand. COVID-19 is putting our methods to the ultimate test and gives us a glimpse of what the future looks like.